Cannabix Technologies Inc (TSE:BLO)
:BLO
Want to see TSE:BLO full AI Analyst Report?
Top Page
Cannabix Technologies
(BLO)
Select Model
Select Model
Rating:47Neutral
Price Target:
C$0.63
▲(5.00% Upside)
Action:Reiterated
Date:04/01/26
The score is held down primarily by weak financial performance—persistent losses, negative margins, and ongoing cash burn that implies financing dependence—despite low leverage. Technicals are a partial positive with the price trading above key moving averages and neutral momentum readings. Valuation remains a secondary drag because negative earnings make P/E less meaningful and there is no dividend support.
Positive Factors
Low leverage / balance sheet solvency
Low leverage meaningfully reduces near-term solvency risk and preserves financial flexibility over the next several months. For a development-stage device company, modest debt improves ability to pursue R&D, regulatory pathways, and partnership negotiations without immediate debt-service pressure, supporting durability while cash burn is addressed.
Negative Factors
Persistent negative cash flow
Consistent negative operating and free cash flow creates an enduring reliance on external financing, increasing dilution and execution risk. Over a 2–6 month horizon this constrains R&D, regulatory submissions, and commercialization efforts; absent fresh capital the company may be forced to slow programs or seek value-eroding funding.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage / balance sheet solvency
Low leverage meaningfully reduces near-term solvency risk and preserves financial flexibility over the next several months. For a development-stage device company, modest debt improves ability to pursue R&D, regulatory pathways, and partnership negotiations without immediate debt-service pressure, supporting durability while cash burn is addressed.
Read all positive factors
Cannabix Technologies (BLO) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$78.45M
Dividend YieldN/A
Average Volume (3M)36.45K
Price to Earnings (P/E)―
Beta (1Y)0.34
Revenue GrowthN/A
EPS Growth-84.43%
CountryCA
EmployeesN/A
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-0.05
Shares Outstanding122,584,110
10 Day Avg. Volume30,616
30 Day Avg. Volume36,452
Financial Highlights & Ratios
PEG Ratio-0.30
Price to Book (P/B)27.07
Price to Sales (P/S)0.00
P/FCF Ratio-37.13
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Cannabix Technologies Business Overview & Revenue Model
Company Description
Cannabix Technologies Inc. is a technology enterprise focused on producing cannabis breath-testing equipment for various users, including employers, legal authorities, government entities, and the general public throughout North America. The compa...
How the Company Makes Money
null...
Cannabix Technologies Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
48
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Jul 2025 | Jul 2024 | Jul 2023 | Jul 2022 | Jul 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 158.50K | 0.00 | 0.00 | 0.00 | 0.00 | 6.57M |
| Gross Profit | -103.03K | -168.52K | -153.24K | -126.29K | -29.22K | -25.57K |
| EBITDA | -6.09M | -4.55M | -2.96M | -2.01M | -3.11M | -9.11M |
| Net Income | -6.26M | -4.69M | -3.13M | -2.14M | -3.37M | -9.24M |
Balance Sheet | ||||||
| Total Assets | 1.83M | 3.00M | 4.70M | 6.95M | 8.76M | 10.38M |
| Cash, Cash Equivalents and Short-Term Investments | 1.26M | 2.35M | 4.26M | 6.52M | 8.45M | 10.10M |
| Total Debt | 51.31K | 158.65K | 154.58K | 132.54K | 0.00 | 0.00 |
| Total Liabilities | 256.13K | 447.71K | 248.02K | 237.17K | 120.84K | 80.78K |
| Stockholders Equity | 1.57M | 2.55M | 4.45M | 6.71M | 8.64M | 10.30M |
Cash Flow | ||||||
| Free Cash Flow | -1.88M | -1.86M | -2.11M | -2.00M | -2.13M | -1.79M |
| Operating Cash Flow | -1.87M | -1.84M | -2.08M | -1.97M | -2.13M | -1.71M |
| Investing Cash Flow | -1.12K | -17.54K | -30.96K | -28.65K | -4.59K | -121.81K |
| Financing Cash Flow | 276.00K | -58.47K | -143.53K | 10.88K | 492.50K | 3.49M |
Cannabix Technologies Technical Analysis
Neutral
0.60
Price Trends
0.71
Negative
0.66
Negative
0.60
Positive
Market Momentum
-0.02
Positive
44.00
Neutral
17.98
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:BLO, the sentiment is Neutral. The current price of 0.6 is below the 20-day moving average (MA) of 0.67, below the 50-day MA of 0.71, and below the 200-day MA of 0.60, indicating a neutral trend. The MACD of -0.02 indicates Positive momentum. The RSI at 44.00 is Neutral, neither overbought nor oversold. The STOCH value of 17.98 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for TSE:BLO.
Cannabix Technologies Peers Comparison
UnderperformOutperform
Sector (51)
TSE:BLO
Cannabix Technologies
0.64
0.00
0.00%
TSE:PINK
Perimeter Medical Imaging AI
0.29
0.06
28.89%
TSE:VPT
VentriPoint Diagnostics
0.13
0.01
8.33%
Cannabix Technologies Corporate Events
Business Operations and StrategyProduct-Related Announcements
Cannabix Delivers Marijuana Breath Test System to Major Virginia Manufacturer
Positive
Apr 2, 2026
Cannabix Technologies has completed a commercial delivery of its Marijuana Breath Test system to a major industrial manufacturing client in Virginia via an authorized reseller, underscoring growing adoption of its non-invasive breath-based tools. ...
Business Operations and StrategyProduct-Related Announcements
Cannabix Lands First Commercial Sale of Marijuana Breath Test to Major Construction Firm
Positive
Mar 19, 2026
Cannabix Technologies has recorded its first commercial sale of the Marijuana Breath Test (MBT) system to a major Pacific Northwest construction contractor through an authorized reseller, marking its initial penetration into the construction secto...
Business Operations and StrategyProduct-Related Announcements
Cannabix launches commercial marijuana breath test targeting recent cannabis use
Positive
Mar 16, 2026
Cannabix Technologies has begun a phased commercial rollout of its Marijuana Breath Test system, delivering units to select customers in multiple industries and preparing to scale production. The platform combines a handheld Breath Collection Unit...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.